EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas

Autores
Varela, Mirta; Ranuncolo, Stella Maris; Morandi, Ana; Lastiri, José; Bal, Elisa Dora; Puricelli, Lydia Ines; Pallotta, María Guadalupe
Año de publicación
2004
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background and Objectives: Therapy of malignant glioma tumors is based on histology and clinical factors. However, comparable lesions may correspond with important prognostic differences. Our purpose was to analyze retrospectively the prognostic input of platelet-derived growth factor receptor (PDGF-R), epidermal growth factor (EGF-R), and bcl-2 expression in 103 malignant gliomas from uniformly treated patients. Methods: The expression of the antigens was analyzed by immunohistochemistry (IHC). Prognostic evaluation was performed with the multivariate proportional hazards model. The follow-up period lasted 19 (5–122) months for survivors. Results: We observed that almost 50% of gliomas showed high expression of PDGFR, while a lower expression of EGF-R and bcl-2 was found. No association between the main prognostic factors in malignant glioma (sex, age, histological grade, and Karnofsky score) and the labeling index (LI) of these antigens was observed. We found that only PDGF-R and EGF-R overexpression were associated with a shorter survival in patients with World Health Organization (WHO) II astrocytomas, being both associations independent of known prognostic factors, as shown by Cox model. Besides, we confirmed other authors’ results that high histological grade and low performance score were associated with worse prognosis. Conclusions: PDGF-R and EGF-R expression could be relevant in determining the prognosis of low-grade astrocytomas (LGAs) and in providing a more objective mechanism for their classification.
Fil: Varela, Mirta. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Morandi, Ana. Hospital Italiano; Argentina
Fil: Lastiri, José. Hospital Italiano; Argentina
Fil: Bal, Elisa Dora. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Puricelli, Lydia Ines. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Pallotta, María Guadalupe. Hospital Italiano; Argentina
Materia
Tumor marker
Malignant Glioma
Invasion
EGF-R
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/242055
Acceder
id CONICETDig_5bff85304e93c62c1d0a492b83474241
oai_identifier_str oai:ri.conicet.gov.ar:11336/242055
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomasVarela, MirtaRanuncolo, Stella MarisMorandi, AnaLastiri, JoséBal, Elisa DoraPuricelli, Lydia InesPallotta, María GuadalupeTumor markerMalignant GliomaInvasionEGF-Rhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background and Objectives: Therapy of malignant glioma tumors is based on histology and clinical factors. However, comparable lesions may correspond with important prognostic differences. Our purpose was to analyze retrospectively the prognostic input of platelet-derived growth factor receptor (PDGF-R), epidermal growth factor (EGF-R), and bcl-2 expression in 103 malignant gliomas from uniformly treated patients. Methods: The expression of the antigens was analyzed by immunohistochemistry (IHC). Prognostic evaluation was performed with the multivariate proportional hazards model. The follow-up period lasted 19 (5–122) months for survivors. Results: We observed that almost 50% of gliomas showed high expression of PDGFR, while a lower expression of EGF-R and bcl-2 was found. No association between the main prognostic factors in malignant glioma (sex, age, histological grade, and Karnofsky score) and the labeling index (LI) of these antigens was observed. We found that only PDGF-R and EGF-R overexpression were associated with a shorter survival in patients with World Health Organization (WHO) II astrocytomas, being both associations independent of known prognostic factors, as shown by Cox model. Besides, we confirmed other authors’ results that high histological grade and low performance score were associated with worse prognosis. Conclusions: PDGF-R and EGF-R expression could be relevant in determining the prognosis of low-grade astrocytomas (LGAs) and in providing a more objective mechanism for their classification.Fil: Varela, Mirta. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Morandi, Ana. Hospital Italiano; ArgentinaFil: Lastiri, José. Hospital Italiano; ArgentinaFil: Bal, Elisa Dora. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Puricelli, Lydia Ines. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Pallotta, María Guadalupe. Hospital Italiano; ArgentinaWiley-liss, div John Wiley & Sons Inc.2004-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/242055Varela, Mirta; Ranuncolo, Stella Maris; Morandi, Ana; Lastiri, José; Bal, Elisa Dora; et al.; EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas; Wiley-liss, div John Wiley & Sons Inc.; Journal of Surgical Oncology; 86; 1; 4-2004; 34-400022-4790CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.20036info:eu-repo/semantics/altIdentifier/doi/10.1002/jso.20036info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:23:38Zoai:ri.conicet.gov.ar:11336/242055instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:23:38.754CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
title EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
spellingShingle EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
Varela, Mirta
Tumor marker
Malignant Glioma
Invasion
EGF-R
title_short EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
title_full EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
title_fullStr EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
title_full_unstemmed EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
title_sort EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas
dc.creator.none.fl_str_mv Varela, Mirta
Ranuncolo, Stella Maris
Morandi, Ana
Lastiri, José
Bal, Elisa Dora
Puricelli, Lydia Ines
Pallotta, María Guadalupe
author Varela, Mirta
author_facet Varela, Mirta
Ranuncolo, Stella Maris
Morandi, Ana
Lastiri, José
Bal, Elisa Dora
Puricelli, Lydia Ines
Pallotta, María Guadalupe
author_role author
author2 Ranuncolo, Stella Maris
Morandi, Ana
Lastiri, José
Bal, Elisa Dora
Puricelli, Lydia Ines
Pallotta, María Guadalupe
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Tumor marker
Malignant Glioma
Invasion
EGF-R
topic Tumor marker
Malignant Glioma
Invasion
EGF-R
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background and Objectives: Therapy of malignant glioma tumors is based on histology and clinical factors. However, comparable lesions may correspond with important prognostic differences. Our purpose was to analyze retrospectively the prognostic input of platelet-derived growth factor receptor (PDGF-R), epidermal growth factor (EGF-R), and bcl-2 expression in 103 malignant gliomas from uniformly treated patients. Methods: The expression of the antigens was analyzed by immunohistochemistry (IHC). Prognostic evaluation was performed with the multivariate proportional hazards model. The follow-up period lasted 19 (5–122) months for survivors. Results: We observed that almost 50% of gliomas showed high expression of PDGFR, while a lower expression of EGF-R and bcl-2 was found. No association between the main prognostic factors in malignant glioma (sex, age, histological grade, and Karnofsky score) and the labeling index (LI) of these antigens was observed. We found that only PDGF-R and EGF-R overexpression were associated with a shorter survival in patients with World Health Organization (WHO) II astrocytomas, being both associations independent of known prognostic factors, as shown by Cox model. Besides, we confirmed other authors’ results that high histological grade and low performance score were associated with worse prognosis. Conclusions: PDGF-R and EGF-R expression could be relevant in determining the prognosis of low-grade astrocytomas (LGAs) and in providing a more objective mechanism for their classification.
Fil: Varela, Mirta. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ranuncolo, Stella Maris. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Morandi, Ana. Hospital Italiano; Argentina
Fil: Lastiri, José. Hospital Italiano; Argentina
Fil: Bal, Elisa Dora. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Puricelli, Lydia Ines. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Pallotta, María Guadalupe. Hospital Italiano; Argentina
description Background and Objectives: Therapy of malignant glioma tumors is based on histology and clinical factors. However, comparable lesions may correspond with important prognostic differences. Our purpose was to analyze retrospectively the prognostic input of platelet-derived growth factor receptor (PDGF-R), epidermal growth factor (EGF-R), and bcl-2 expression in 103 malignant gliomas from uniformly treated patients. Methods: The expression of the antigens was analyzed by immunohistochemistry (IHC). Prognostic evaluation was performed with the multivariate proportional hazards model. The follow-up period lasted 19 (5–122) months for survivors. Results: We observed that almost 50% of gliomas showed high expression of PDGFR, while a lower expression of EGF-R and bcl-2 was found. No association between the main prognostic factors in malignant glioma (sex, age, histological grade, and Karnofsky score) and the labeling index (LI) of these antigens was observed. We found that only PDGF-R and EGF-R overexpression were associated with a shorter survival in patients with World Health Organization (WHO) II astrocytomas, being both associations independent of known prognostic factors, as shown by Cox model. Besides, we confirmed other authors’ results that high histological grade and low performance score were associated with worse prognosis. Conclusions: PDGF-R and EGF-R expression could be relevant in determining the prognosis of low-grade astrocytomas (LGAs) and in providing a more objective mechanism for their classification.
publishDate 2004
dc.date.none.fl_str_mv 2004-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/242055
Varela, Mirta; Ranuncolo, Stella Maris; Morandi, Ana; Lastiri, José; Bal, Elisa Dora; et al.; EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas; Wiley-liss, div John Wiley & Sons Inc.; Journal of Surgical Oncology; 86; 1; 4-2004; 34-40
0022-4790
CONICET Digital
CONICET
url http://hdl.handle.net/11336/242055
identifier_str_mv Varela, Mirta; Ranuncolo, Stella Maris; Morandi, Ana; Lastiri, José; Bal, Elisa Dora; et al.; EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas; Wiley-liss, div John Wiley & Sons Inc.; Journal of Surgical Oncology; 86; 1; 4-2004; 34-40
0022-4790
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.20036
info:eu-repo/semantics/altIdentifier/doi/10.1002/jso.20036
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781766868664321
score 12.982451

Publicaciones similares